Team Science (The Liver Health Study)

Team Science to Identify & Intervene on Metabolism- & Alcohol-Associated Liver Disease

NCT06924281•Brown University

Summary

Liver damage from alcohol intake and weight-related behaviors is preventable and treatable only through lifestyle changes. This mixed-methods randomized controlled trial compares standard and enhanced approaches to screening, brief intervention, and referral to treatment/prevention (SBIRT/P) to identify and intervene for metabolism- and alcohol-associated liver disease (MetALD). Our multidisciplinary team aims to show that integrating results of noninvasive liver screening with Fibroscan®, a painless ultrasound that measures stiffness and fat in the liver, can optimize our brief intervention. The study population is adults age 21+ who speak Spanish or English from underresourced communities with alcohol- and weight-related risks for MetALD.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Be at least 21 years of age.
•Exceed alcohol intake screening guidelines for MetALD.
•Have a Body Mass Index (BMI) \>=25 kg/m2.
•Be able to speak and read English or Spanish to provide written informed consent and understand written and oral instructions in English or Spanish.

Exclusion Criteria

•Pre-existing liver disease or hepatocellular carcinoma or prior liver transplant.
•Pre-existing medical conditions that, in the opinion of the investigative team, would interfere with research participation (e.g., loss of kidney function, uncontrolled infections, multiorgan failure, uncontrolled upper gastrointestinal bleeding, other active malignancies except skin cancer).
•Pre-existing mental health conditions that, in the opinion of the investigative team, would interfere with the ability to provide informed consent and understand written and oral instructions (e.g., hepatic encephalopathy, psychotic disorder diagnosis or symptoms).
•Current pregnancy.
•Be anyone who, based on self-reported withdrawal symptoms and the opinion of the investigative team, could not currently safely be withdrawn from alcohol without medical detoxification.
•Currently receiving formalized psychosocial treatment for an alcohol use or drug problem and/or newly taking medications for an alcohol use or drug problem.
•Currently receiving formalized behavioral weight management treatment and/or newly taking weight loss medications.

Locations (1)

Clinica Esperanza Hope Clinic

Providence, Rhode Island, United States

Key Dates

Start Date

April 25, 2025

Primary Completion Date

August 29, 2025

Completion Date

August 31, 2025

Last Updated

February 4, 2026

Enrollment

ACTUAL participants

Conditions

Steatotic Liver Disease of Mixed Origin (MetALD)

Interventions

Brief motivational interviewing with personalized feedback

BEHAVIORAL

Brief motivational interviewing with standard health information

BEHAVIORAL

Investigating Myosteatosis in Steatotic Liver Diseases

NCT06514300

View study

NOT_YET_RECRUITING

Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)

NCT06907563

Steatotic Liver DiseaseMASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions